Physician profile
Farida Abid
NPI 1629007588
$50,192.38
in general payments reported to CMS, 2019-2025
8 companies · $17.84 in 2025
The $17.84 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,455 · 2020: $7,866 · 2021: $3,950 · 2022: $21K · 2023: $767 · 2024: $7,077 · 2025: $17.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $6,000 · Travel and Lodging: $853 · Consulting Fee: $488 · Food and Beverage: $447 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $6,000.00 |
| Travel and Lodging | $853.04 |
| Consulting Fee | $487.50 |
| Food and Beverage | $446.68 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sarepta Therapeutics, INC. | $27,737.08 | 2019-2023 | |
| Ptc Therapeutics, INC. | $13,134.49 | 2019-2023 | |
| Catalyst Pharmaceuticals, INC. | $7,077.43 | 2024 | |
| Ns Pharma, INC. | $1,347.80 | 2021-2023 | Viltepso |
| Vertex Pharmaceuticals Incorporated | $487.50 | 2023 | |
| Biogen, INC. | $344.10 | 2020-2025 | Spinraza, Spinraza |
| Genentech, INC. | $34.32 | 2023 | Evrysdi |
| Pfizer INC. | $29.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farida Abid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.